Mar. 29 at 12:50 AM
$KZIA The strong point of difference - and competitive advantage is the ability of paxalisib to penetrate the so called, blood brain barrier. Already the company has had strong clinical brain metastases success, in a Memorial Sloan Ketting Phase 1 study. This highly credible trial was expanded to Miami Cancer Inst and Fred Hutchinsons Cente Seattle. Subsequent to the trial, the FDA awarded Fast Track designation in 2023. (paxalisib &radiation). The current study in Brisbane, has shown outstanding initial success with body metastatic cancer. It is understood remaining patients with be selected harboring TNBC PIK3CA (PI3K) CNS mutations - where there are limited treatment options - and life expectancy of a few months. Despite its float size, Paxalisib is on the cusp of distinguishing itself, as the premier drug in this mutli billion dollars PI3K (mTOR) red hot, drug class. Outstanding opportunity here. The company has
$45M cash.
